Status:
NOT_YET_RECRUITING
Preventing Breast Cancer Therapy-related Cardiovascular Toxicity With a Daily-adapted Program With Mhealth Support
Lead Sponsor:
Universidad de Granada
Collaborating Sponsors:
Instituto de Salud Carlos III
Hospital Clinico Universitario San Cecilio
Conditions:
Breast Cancer Female
Eligibility:
FEMALE
18-65 years
Phase:
NA
Brief Summary
ATOPE-PRO, was developed with the intention of consolidating the integration of an innovative system for the prevention of cancer therapy-related cardiovascular toxicity (CTR-CVT) in the continuum car...
Detailed Description
More and more women are experiencing breast cancer at younger ages, yet survival rates have become very promising. However, years after cancer treatment, related sequelae (physical, psychological, or ...
Eligibility Criteria
Inclusion
- Recently diagnosed with stage I-III breast cancer
- Treatments predisposing to cardiotoxicity (anthracyclines, targeted therapies, radiotherapy)
- Signed informed consent form
- Medical authorisation to participate
- Smartphone user level
Exclusion
- Patient underwent previous cancer treatments.
- Patients were previously diagnosed with cancer
- Pregnant patients. Patients performing other type of therapeutic exercise at diagnosis time with an intake \>or = to 150 moderate-intensity or 75 min of vigorous-intensity a day
- Therapeutic exercise practice not recommended because psychiatric or cognitive disorders or cute or chronic condition that prevents exercise (advanced lung disease, oxygen requirement, stenosis \>70%, metastasis etc.).
Key Trial Info
Start Date :
January 10 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT06518200
Start Date
January 10 2026
End Date
December 31 2027
Last Update
November 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Granada
Granada, Spain, 18016